ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
06 Jan 2023 10:58

Hong Kong Buybacks Weekly (Jan 6th): AIA, Tencent, AAC Technologies

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Aia (1299 HK),...

Logo
598 Views
Share
04 Jan 2023 12:14

Hong Kong Connect Flows Monthly: 12 Months of Inflows

We analyzed the Hong Kong Connect Scheme for December and highlight flows for Meituan, HKEX, China Unicom, Shenzhou Intl, Sensetime, Xiaomi, HSBC,...

Logo
492 Views
Share
03 Jan 2023 08:05

Hong Kong Connect Flows (Dec 30th): Tencent, Meituan

We analyzed the Hong Kong Connect Scheme for last week and highlight flows for Tencent Holdings Limited (700 HK) and Meituan (3690 HK).

Logo
510 Views
Share
30 Dec 2022 10:38

Hong Kong Buybacks Weekly (Dec 30th): Tencent, AIA, Productive Technologies

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
777 Views
Share
23 Dec 2022 16:10

Hong Kong Buybacks Weekly (Dec 23rd): Tencent, AIA, GWM

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
760 Views
Share
x